More MS news articles for November 2000

Pathobiotek Reports Joining HARC as an Affiliate
 
http://news.excite.com/news/bw/001113/tx-pathobiotek

Updated 8:03 AM ET November 13, 2000
Current quotes (delayed 20 mins.) PBTK  0.12  0.00  (0.00%)
 
HOUSTON (BUSINESS WIRE) - Pathobiotek Diagnostics Inc. (OTCBB:PBTK)(http://www.Pathobiotek.com), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced its becoming a HARC2(a) (HARC Affiliates Resource Center) Affiliate in the Center for New Enterprise Development at HARC (Houston Advanced Research Center) in The Woodlands, Texas.

Created in 1982, HARC is a not-for-profit, university-linked research, development and service institution addressing state-of-the-art technology and policy issues. The HARC2(a) Affiliates program is designed to accelerate the growth of emerging technology companies. Started in 1997, 15 companies participate in the program. Ranging from small to mid-sized, affiliates are encouraged to collaborate with HARC Centers and collaborative institutions.

Pathobiotek has seized the opportunity to leverage the immense resources of HARC by becoming an Affiliate. The total cost of these resources is miniscule to Pathobiotek as compared to building the Company to a size whereby it could perform most of these tasks with internal people. The infrastructure and professional assistance for small companies allows for cost savings, business opportunities and guidance in many aspects of growing a business at a faster pace. The expectation is that Pathobiotek, working in "The Research Forest," will become a stronger company than in the current location and situation. This is a biotech rich environment with several biotech neighbors.

The "Benefits of Doing Business with HARC" noted herein are taken from the HARC Web site and shortened to save space. You may go to http://.www.harc.edu for the unabridged version.

About Pathobiotek: Pathobiotek develops products for the diagnosis and monitoring of treatment for multiple sclerosis and other immune disorders and license these to qualified strategic partners.

Operations: Pathobiotek is a product development company engaged in the production of diagnostics and other pharmaceutical products for licensing to qualified companies. Among the efforts at Pathobiotek is the research and development based on novel microbial agents discovered at Pathobiotek. Scientists at Pathobiotek have identified an organism that may be associated with symptoms in patients with multiple sclerosis (MS). This organism, known as "Luey", has been detected in more than 800 patient samples over a 5 five-year period. Pathobiotek has conducted preliminary studies that have shown a 100% correlation between clinical improvement and reduction of levels of this organism in the patient. A similar correlation with this organism has been seen in the treatment of other disorders such as Chronic Fatigue Syndrome (CFS) and certain other immune disorders.

Additional information on Pathobiotek Diagnostics Inc. can be obtained by calling 713/939-1833, Ext. 300; e-mailing pbtkinfo@thestockadvisor.com or by visiting the Web site at http://www.Pathobiotek.com or e-mail irag@harc.edu. For more information on the HARC affiliates program, contact Phil Ralston at 281/364-6026. Affiliate companies are independently owned and operated. The Houston Advanced Research Center assumes no responsibility for statements made in this release.

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the company's domestic and international operations, imprecision in estimating product reserves and the company's ability to replace and expand its holdings.

(a) Numeral is a superscript.

Contact: Pathobiotek Diagnostics Inc., Houston Glinda Fortner, 713/939-1833 Ext. 300 Fax: 713/939-1835 www.Pathobiotek.com